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background: The Wolff-Parkinson-White (WPW) syndrome is characterized by symptomatic supraventricular tachycardia and an ECG with pre-
excitation of the QRS complex. Individuals with the WPW syndrome have an orthodromic conducting accessory pathway that connects the atria and 
the ventricles. The prevailing treatment of the WPW syndrome is a radiofrequency ablation (RFA) of the accessory pathway. The objective of this study 
was to assess the mortality in patients undergoing RFA for the WPW syndrome and to identify independent risk factors for post-ablation mortality and 
atrial fibrillation (afib) after the RFA.
methods: A retrospective case-control study of all patients (N=362) subjected to RFA of the WPW syndrome at Aarhus University Hospital from 
1990 to 2011. A control group (N=3619) was generated from the Danish National Board of Health Central Population Registry. Survival data was 
obtained from the Danish National Board of Health ”cause of death database”. Data on post-ablation morbidity including post-ablation afib were 
obtained from the Danish National Patient Registry.
results: We found no significant difference in all-cause mortality when comparing the WPW group with control group (HR 0,77 CI 0.47-1.25). A 
subgroup analyses on the WPW group showed that cardiac arrest prior to ablation was a significant risk factor for post-ablation mortality (HR 7.32 CI 
1.33-40.39). Comparing the two groups we found that the WPW syndrome was a significant risk factor for post-ablation atrial fibrillation (HR of 5.87 
CI 3.90-8.85). When identifying risk factors for post-ablation afib within the WPW group, we found that afib prior to ablation (HR 3.36 CI 1.67-6.77) 
and pseudoventricular tachycardia (HR 2.98 CI 1.27-7.03) prior to ablation were independent risk factors.
conclusion: Patients with RFA treated WPW syndrome have a post-ablation mortality that is similar to the background population. Even when 
subjected to RFA treatment, the WPW syndrome is a significant risk factor for atrial fibrillation.
